Intermittent hormone therapy (IHT) as opposed to continuous hormone therapy (CHT) provides a better quality of life (QoL) for men with locally advanced prostate cancer. However, there is a debate created by a few major research protocols that have been inconclusive as to the difference in achieving the ultimate goal, survival despite prostate cancer. Researchers [...]
Clinical trials for treatment of men with advanced prostate cancer often don’t include men who are considered very elderly (aged over 80 years). So, even if we know that a treatment is tolerable and effective in the average man, we can not assume that it would also be in the very elderly, especially in reference [...]
Increasingly, we have become better informed about the possible role of psychological and spiritual interventions in the treatment of cancer, specifically for this post in men with locally advanced prostate cancer. This post is limited to just discussing the possible interventions specifically in men with a Biochemical Prostate Cancer Recurrence, commonly referred to as a [...]
Provenge, despite its demonstrated survival advantage, continues to be knocked as a viable treatment for men with castrate-resistant prostate cancer. What is Provenge? Provenge is immunotherapy for men with metastatic castrate-resistant prostate cancer. In other words, Provenge might help men live longer after their cancer has spread outside of the prostate and are no [...]
JAMA Oncology has published a new study that suggests that adding a statin drug at the initiation of hormone therapy (ADT) to the treatment protocol for a man with progressive, hormone-sensitive prostate cancer may significantly impact their actual time to disease progression (TTP). Historically, we know Statin use has been associated with improved prostate cancer [...]